Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial영국에서 2 가지 용량의 Chadox1 NCOV-19 또는 BNT162B2에 따른 3 가지 용량 (부스터)으로서 7 개의 코비드 -19 백신의 안전성 및 면역 원성Clinical Trial Published on 2021-12-182022-08-13 Journal: Lancet (London, England) [Category] Fulltext, SARS, 임상, [키워드] 95% CI Ad26 Ad26.COV2.S adverse event age anti-Spike IgG antibody assigned blinded BNT BNT162b2 booster booster vaccination booster vaccines cellular response Cellular responses ChAd ChAdOx1 ChAdOx1 nCoV-19 Control control group control groups Course COV-BOOST COVID-19 COVID-19 vaccine CureVac CVn CVnCoV dose eligibility criteria ELISA female finding FIVE funding generate geometric mean geometric mean ratio geometric mean ratios GMR GMRs group humoral Humoral and cellular responses immunogenicity individuals initial intention-to-treat population investigated IQR ISRCTN janssen laboratory-confirmed SARS-CoV-2 infection Local m1273 median age MenACWY meningococcal conjugate vaccine Moderna modified intention-to-treat mRNA1273 multicentre neutralising response neutralising responses Novavax NVX NVX-CoV2373 Older Older age outcome Pain participant Participants Pfizer Phase 2 phase 2 trial primary analysis quadrivalent meningococcal conjugate vaccine randomised Randomly ranged reactogenicity referred to Registered Safety SARS-COV-2 infection screened secondary Secondary outcomes Serious Adverse Events Seven spike IgG systemic adverse events the median three group three groups treat treatment allocation Trial Vaccine vaccine availability Valneva Viral viral neutralisation VLA2001 were assessed were blinded white wild-type [DOI] 10.1016/S0140-6736(21)02717-3 PMC 바로가기 [Article Type] Clinical Trial
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants이종 Chadox1 NCOV-19 및 BNT162B2 프라임-부스트 백신 접종은 유능한 SARS-COV-2 변이체에 대한 강력한 중화 항체 반응 및 T 세포 반응성을 유도합니다.Clinical Trial Published on 2021-12-172022-08-13 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] addition Administered Adverse reactions All participants Alpha analysed antibody titres ART Arts B.1.1.7 B.1.351 B.1.617.1 B.1.617.2 Beta BNT162b2 boost CD4 CD8 Cellular immune response cellular immune responses ChAdOx1 ChAdOx1 nCoV-19 Cohort Course COVID-19 COVID-19 vaccination Delta dominant elicit elicited European evaluate finding followed by foundation funding Gamma Germany Heterologous heterologous vaccination homologous Horizon humoral immune immune responses Immunity immunogenic Immunological response immunological responses individual induce Lower median mRNA-based vaccine mRNA-based vaccines nCoV neutralization neutralized Neutralizing activity Neutralizing antibody response no difference offer P.1 participant peptide peptides prevalent Protective reactive reactivity reactogenicity receiving recognize regimen Research resulting retained Robert Koch SARS-CoV-2 spike peptide SARS-CoV-2 variant SARS-CoV-2 variants Science sera Serious Adverse Event Serious Adverse Events serological data significantly Symptom T cell T cells tested titre union vaccination variant variants variants of concern Wuhan Wuhan-Hu-1 [DOI] 10.1016/j.ebiom.2021.103761 PMC 바로가기 [Article Type] Clinical Trial
BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunityObservational Study Published on 2021-12-172022-10-05 Journal: Vaccine [Category] SARS, 임상, [키워드] BNT162b2 mRNA BNT162b2 mRNA vaccine BNT162b2 vaccine Booster effect cellular immunity COVID-19 COVID-19 vaccine COVID-19 vaccines cross-reactivity elicited examined first dose HCW HCWs healthcare worker Immunity individuals Infection Level reactogenicity reduce Registered Registration reported SARS-CoV-2 second dose significantly more systemic reaction T-cell T-cell responses These data vaccination Vaccine [DOI] 10.1016/j.vaccine.2021.10.074 PMC 바로가기 [Article Type] Observational Study
Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and LifestyleArticle Published on 2021-12-132022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] acquisition adverse effect age antibody assays AZD1222 blood sample BMI body mass cellular Cellular immune response cellular immunity ChAdOx1 nCoV-19 chill collected correlated correlation creatinine ELISA female had no Health Health status humoral Humoral immunity identify IgG Immunity immunogenicity individual intensity investigated muscle mass neutralizing antibody Questionnaires Rash reactogenicity reflect response SARS-CoV-2 SARS-CoV-2 neutralizing antibody second second dose Sex Side effects status vaccination Vaccine Vaccines virus neutralization test were used [DOI] 10.3390/vaccines9121473 PMC 바로가기 [Article Type] Article
Cardiomyopathy Associated with Anti-SARS-CoV-2 Vaccination: What Do We Know?Review Published on 2021-12-132022-10-28 Journal: Viruses [Category] COVID-19, SARS, [키워드] administration Adults adverse effect age Autoimmune response Characteristics clinically COVID-19 death described develop dose Effect effective effort Epidemiology event Evolution exacerbated General population greater highlighting Hospitalization immune response lack less manifested mechanism Messenger RNA Mild moderate morbidity and mortality myocarditis Pediatric patients Pericarditis Prevent Prognosis Proteins reactogenicity responsible SARS-CoV-2 SARS-CoV-2 pandemic severity Symptom Vaccines [DOI] 10.3390/v13122493 PMC 바로가기 [Article Type] Review
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialClinical Trial Published on 2021-12-112022-10-05 Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, [키워드] 1:1 95% CI absence Administered Adults adverse event age Analysis anaphylaxis assigned Bharat chronic conditions clinical Clinical efficacy clinical trial clinically clinics computer-generated Council COVID-19 COVID-19 infection Cutoff deaths dependent on distribution dose double-blind Efficacy evaluate Follow-up groups healthy hospital immunocompromising condition immunological immunosuppressive inactivated India interim analysis intramuscular dose investigators laboratory-confirmed median medical condition multicentre Nurse occurred Occurrence outcome outcomes participant Participants per-protocol population Phase 3 phase 3 trial Placebo placebo group placebo recipients placebo-controlled Primary outcome proportion raised randomisation randomised Randomly reactogenicity receive recipient recruited Registered registry reported Research safety population SARS-CoV-2 vaccine second dose Serious Adverse Event seronegative participant severity significant difference Sponsor stratified study population symptomatic symptomatic COVID-19 disease the vaccine therapy Toll-like receptor Treatment treatment group Trial Vaccine virion [DOI] 10.1016/S0140-6736(21)02000-6 PMC 바로가기 [Article Type] Clinical Trial
Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccineLetter to the Editor Published on 2021-12-032022-11-01 Journal: Cell Research [Category] COVID-19, [키워드] booster CoronaVac dose immunology Inactivated vaccine Molecular biology reactogenicity ZF2001 [DOI] 10.1038/s41422-021-00596-5 PMC 바로가기 [Article Type] Letter to the Editor
Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy이탈리아 밀라노의 COVID-19 위탁 병원에서 의료 종사자의 BNT162b2 mRNA COVID-19 백신에 대한 항체 반응에 대한 이전 감염 상태의 영향Article Published on 2021-12-022022-09-11 Journal: Human vaccines & immunotherapeutics [Category] SARS, 진단, 치료기술, [키워드] 95% CI adjusted odds ratio anti-S IgG anti-SARS-CoV-2 Antibody Response BNT162b2 BNT162b2 mRNA BNT162b2 vaccine COVID-19 COVID-19 vaccine detectable dose effective elapsed enrolled Fever first dose HCW HCWs healthcare healthcare worker Healthcare workers hospital humoral Humoral response IgG levels Impact Infection Italy Mild mild to moderate moderate mRNA vaccine naïve subjects occurred of BNT162b2 reactogenicity receive reported risk SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination Serious Adverse Event Serious Adverse Events serological serological response Side effect single dose spike IgG subject subjects the median the vaccine Vaccine [DOI] 10.1080/21645515.2021.2002639 PMC 바로가기 [Article Type] Article
Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines화이자 및 아스트라제네카 코로나19 백신의 반응원성과 면역원성Immunology Published on 2021-12-012022-09-11 Journal: Frontiers in Immunology [Category] MERS, SARS, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus age antibody AstraZeneca collected Complication coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 vaccine cross-sectional cross-sectional study Effectiveness ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Factor groups Health status Height homologous humoral immune response IgG antibodies immunogenicity injection injection site participant Participants Pfizer proportion Randomly reactogenicity receipt recipient recipients reported respiratory Result SARS-CoV-2 SARS-CoV-2 spike protein Saudi Arabia selected Seropositivity Side effect significantly higher specific IgG antibodies Spike protein spike-specific IgG antibodies Spike-specific IgG antibody Symptom the SARS-CoV-2 total score vaccination Vaccine vaccine dose vaccine doses Vaccines weight women [DOI] 10.3389/fimmu.2021.794642 PMC 바로가기 [Article Type] Immunology
Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case seriesSLE 환자에서 CoronaVac 비활성화 SARS-CoV-2 백신에 따른 이종 부스터의 면역원성, 안전성 및 반응성: 사례 시리즈Article Published on 2021-12-012022-09-12 Journal: RMD Open [Category] SARS, 진단, [키워드] Autoimmune booster booster dose case sery Cellular immune response CoronaVac country COVID-19 COVID-19 pandemic disease elicited Emergency use heterogeneous heterogenous humoral immune response immunogenicity Immunosuppressed immunosuppressive immunosuppressive medications IMPROVE inactivated Inactivated vaccine inactive initial lupus erythematosus mRNA Patient reactogenicity SARS-CoV-2 vaccination SARS-CoV-2 vaccine SLE Support systemic systemic lupus erythematosus therapy vaccination Vaccine Viral vector Viral vector vaccine [DOI] 10.1136/rmdopen-2021-002019 PMC 바로가기 [Article Type] Article